Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
07:06 | EXOPHARM LIMITED: Change of Director's Interest Notice - MD | - | ASX | ||
07:05 | EXOPHARM LIMITED: Change of Director's Interest Notice - CB | - | ASX | ||
07:04 | EXOPHARM LIMITED: Final Director's Interest Notice - ID | - | ASX | ||
06:24 | EXOPHARM LIMITED: Ceasing to be a substantial holder - Altnia | - | ASX | ||
01:25 | EXOPHARM LIMITED: Notification regarding unquoted securities - EX1 | - | ASX | ||
01:16 | EXOPHARM LIMITED: Notification regarding unquoted securities - EX1 | - | ASX | ||
01:12 | EXOPHARM LIMITED: Notification regarding unquoted securities - EX1 | - | ASX | ||
01:11 | EXOPHARM LIMITED: Application for quotation of securities - EX1 | - | ASX | ||
01:11 | EXOPHARM LIMITED: Application for quotation of securities - EX1 | - | ASX | ||
01:11 | EXOPHARM LIMITED: Application for quotation of securities - EX1 | - | ASX | ||
01:08 | EXOPHARM LIMITED: Application for quotation of securities - EX1 | - | ASX | ||
Mi | Tryp Therapeutics Inc: Tryp completes plan of arrangement with Exopharm | 3 | Stockwatch | ||
Mi | Tryp Therapeutics and Exopharm Limited Announce Completion of Plan of Arrangement | 246 | ACCESSWIRE | KELOWNA, BC / ACCESSWIRE / May 1, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF) and Exopharm Limited ACN 163 765 991 ("Exopharm") are pleased to announce that completion... ► Artikel lesen | |
Mo | EXOPHARM LIMITED: Proposed issue of securities - EX1 | - | ASX | ||
So | EXOPHARM LIMITED: Quarterly Activities Report and Appendix 4C | - | ASX | ||
25.04. | Tryp Therapeutics Set To Finalize Merger With Exopharm, Announces Trading Halt Ahead Of ASX Listing | 8 | Benzinga.com | ||
24.04. | Tryp Therapeutics Inc: Tryp target Exopharm receives shareholder OK | 6 | Stockwatch | ||
24.04. | Tryp Therapeutics Provides Update on Plan of Arrangement With Exopharm Limited and Announces Voluntary Trading Halt | 200 | ACCESSWIRE | KELOWNA, BC / ACCESSWIRE / April 24, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF) is pleased to announce that the shareholders of Exopharm Limited ACN 163 765 991... ► Artikel lesen | |
22.04. | EXOPHARM LIMITED: Change of Director's Interest Notice - CB | - | ASX | ||
22.04. | EXOPHARM LIMITED: Change of Director's Interest Notice - MD | - | ASX |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
VERA THERAPEUTICS | 43,500 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
JANUX THERAPEUTICS | 62,43 | 0,00 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
SPRINGWORKS THERAPEUTICS | 43,320 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
APOGEE THERAPEUTICS | 52,20 | 0,00 % | Apogee Therapeutics, Inc.: Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases | Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 19,290 | 0,00 % | Edgewise Therapeutics: Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies | Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designations for sevasemten... ► Artikel lesen | |
EVOTEC | 9,780 | -1,16 % | Deutsche Bank, Evotec, HelloFresh, Renk, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 25,580 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 8,790 | 0,00 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
C4 THERAPEUTICS | 6,430 | 0,00 % | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
CG ONCOLOGY | 39,500 | 0,00 % | CG Oncology Inc.: CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 | ||
AMGEN | 295,00 | +13,61 % | Abnehmspritzen in Planung: Kursexplosion: Nicht Apple, sondern Amgen wird heute den Dow Jones anführen! | © Foto: NurPhoto | Jakub Porzyck - picture allianceDie Titel von Amgen konnten sich am Donnerstag in der US-Nachbörse um über 15 Prozent steigern, nachdem das Unternehmen seine Geschäftszahlen bekanntgegeben... ► Artikel lesen | |
QIAGEN | 40,040 | +1,15 % | Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Porsche AG, Philips, Qiagen, Vivendi und Bawag Group | © Foto: Porsche AG NewsroomGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:55... ► Artikel lesen | |
ALX ONCOLOGY | 16,620 | 0,00 % | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | ||
CULLINAN THERAPEUTICS | 27,540 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
VENTYX BIOSCIENCES | 4,910 | 0,00 % | Ventyx Biosciences, Inc.: Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event | VTX3232 was well-tolerated in the Phase 1 trial with robust target coverage achieved in both plasma and CSF; Ventyx is planning to initiate Phase 2a trials in Parkinson's disease and obesity in H2... ► Artikel lesen |